HPV 16/18/45 / recomWell
$2,695.00
| Host | Quantity | Applications | Species Reactivity | Data Sheet | |
|---|---|---|---|---|---|
| 96 Tests | ELISA | Human papillomavirus 16/18/45 |  |
Overview
Product Name recomWell HPV 16/18/45 ELISA Kit (7904)
Description Qualitative Enzyme immunoassay for detection of E7 oncoproteins from high risk (hr) Human Papillomavirus (HPV) types 16, 18 and 45 in cervical smears.
Target Human papillomavirus 16/18/45
Product Background Human Papillomaviruses (HPV) are sexually transmitted viruses frequently occurring all over the world. Almost everyone comes into contact with at least one HP virus during the course of his/her life. In most cases, the infection heals on its own. In rare cases, chronic persistent infections can cause health problems. So far, more than 200 virus types are known of which approximately 40 affect the genitals. Some of these viruses are responsible for the formation of benign genital warts while other types, the so-called high risk types, contribute significantly to the development of cervical, anal, and penile carcinoma and cancer in the area of mouth and throat. The high risk HPV types 16 and 18 are found in 70% of cervical cancer. However, type 45 is also highly associated with risk, particularly for adenocarcinoma, a very aggressive type of cervical cancer.
Species Reactivity Human papillomavirus 16/18/45
Applications ELISA
Additional Information Additional Mirkogen Kit Information
Specificity Information
Target ID Human papillomavirus 16/18/45
Research Areas Infectious Disease
Application Images
-7904-1)
-7904-2)
-7904-3)
Description Possible use of recomWell HPV 16 18 45 and the relevance of E7
Due to the diagnostic significance of E7, the new recomWell HPV 16 18 45 can be utilized as a useful additional test in order to take further therapeutic or diagnostic measures.
Due to the diagnostic significance of E7, the new recomWell HPV 16 18 45 can be utilized as a useful additional test in order to take further therapeutic or diagnostic measures.
Description Test principle and procedure.
Description Diagnostic Sensitivity, Diagnostic Specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV)
The sensitivity performance data for the corresponding disease stages were generated by the testing of hrHPV16 or hrHPV18 positive samples (as determined by HPV-NAT). The specificity of the different disease stages was defined as the quotient of negative E7 test results obtained divided by the corresponding total number of true negative (disease-"free") samples.
The sensitivity performance data for the corresponding disease stages were generated by the testing of hrHPV16 or hrHPV18 positive samples (as determined by HPV-NAT). The specificity of the different disease stages was defined as the quotient of negative E7 test results obtained divided by the corresponding total number of true negative (disease-"free") samples.
Additional Information
Components
| Microtiter Plate | 12 x 8 Wells |
| Positive Control | 1700 uL |
| Negative Control | 1700 uL |
| Lysis Buffer A | 50 mL |
| Lysis Buffer B | 50 mL |
| 10X Wash Buffer | 130 mL |
| Biotinylated Detection Antibody | 12 mL |
| Streptavidin-HRP Conjugate | 12 mL |
| TMB Substrate | 12 mL |
| Stop Slution | 12 mL |
| Microplate Sealing Tape | 3 Each |
| Instuctions for Use | 1 Each |
| Evaluation Form | 1 Each |
Handling
Storage Store at 2 - 8ºC. Do not Freeze.
References & Data Sheet
Data Sheet 
Download PDF Data Sheet
Download PDF Data Sheet